What Zenalb 20% Treats: Main Uses and Benefits

Zenalb 20% is an administered protein solution relevant for supportive management in acute care to address severe fluid and protein deficits that significantly affect fluid stability. Its use is generally relevant in two main contexts of supportive management.

---

Supportive Management for Acute Volume Loss

This application addresses the critical need for volume support when fluid has been lost due to significant trauma, extensive bleeding, or major surgical procedures. Albumin solutions in the 20%–25% range are commonly used when volume deficiency is long-standing and accompanied by edema. Zenalb 20% provides the supportive therapeutic benefit of assisting with the maintenance of circulation stability and supporting adequate blood flow to essential organs. It is relevant in urgent clinical situations and helps with managing symptoms associated with circulatory stress.

---

Addressing Critical Protein Deficits and Related Edema

Zenalb 20% is commonly used to manage critically low levels of albumin (hypoalbuminemia), a condition often seen in severe burns, acute liver failure, or certain kidney diseases. By supplying this key protein, the medicine supports the body during periods of systemic imbalance, which provides the benefit of contributing to easing severe fluid misplacement symptoms. This may assist with managing severe symptomatic manifestations such as generalized edema or ascites. Indications commonly include patients dealing with hypovolemia, hypoalbuminemia, and fluid management during therapeutic plasma exchange.

---

Quick Fact: Supportive Management for Severe Edema Zenalb 20% helps manage severe swelling that results from low protein levels by supporting managing the symptoms related to fluid misplacement.

Regulatory References

1. FDA’s guidance on Human Albumin (20-25%)

The eligibility for Zenalb 20% (Human Albumin 20%) is strictly defined by regulatory guidelines, focusing on pre-existing conditions and known allergies.

Populations for Whom Use is Contraindicated

The medicine must not be used in patients with:

• Hypersensitivity (severe allergy) to albumin preparations or any ingredient in the formulation.
• Severe Anemia or Cardiac Failure when it is accompanied by normal or increased blood volume, due to the high risk of circulatory overload.

Populations Requiring Conditional Use

Zenalb 20% should be used with special caution in conditions where hypervolaemia (volume overload) or hemodilution poses a specific risk. These conditions include Decompensated Cardiac Insufficiency, Hypertension, Pulmonary Oedema, Oesophageal Varices, Haemorrhagic Diathesis, and severe Renal Impairment.

Age and Physiological States

Population	Official Eligibility Status
Pediatric Patients	Use is permitted, but the product should only be administered if clearly needed due to limited established data.
Pregnancy/Lactation	Safety has not been established in controlled human trials; use only if clearly needed.

This structure ensures administration is restricted to populations where the labeled risks can be carefully managed.

Interactions with other medicines and products

The official regulatory profile for Zenalb 20% (Human Albumin) primarily details administration constraints and physical incompatibilities rather than metabolic drug interactions. Regulatory documentation explicitly states that no specific interactions of human albumin with other medicinal products are known that would affect clearance or metabolic pathways. This absence of documented pharmacokinetic interactions means that co-administered medicines are not expected to change the exposure or concentration of Zenalb 20% in the body.

The most critical constraints involve physical and chemical incompatibility. Zenalb 20% must not be mixed in the infusion line with several substances, including whole blood, packed red cells, protein hydrolysates, or alcoholic solutions. A mandatory administration rule prohibits dilution with Water for Injections, as official documentation warns this carries a risk of inducing hemolysis in the recipient. Only compatible solutions, such as 0.9% Sodium Chloride or 5% Glucose, are specified as permitted diluents.

Regulatory documents do note a pharmacodynamic co-administration with diuretics. Human Albumin solutions are formally recognized for use alongside an appropriate diuretic medicine to reinforce the diuretic effect in specific clinical situations. No interactions with food, dietary supplements, or herbal products are explicitly documented in official labeling.

Zenalb 20% is a highly concentrated solution of Human Albumin, the principal protein governing plasma oncotic pressure. Its mechanism of action is mediated through two primary physiological functions of albumin within the circulatory system.

Modulation of Plasma Colloid Osmotic Pressure

Zenalb 20% exerts a significant hyper-oncotic effect within the intravascular space due to its high concentration (20%). This property increases the Colloid Osmotic Pressure (COP) differential across the capillary membrane, promoting the shift of interstitial fluid into the circulation. The resulting expansion of the plasma volume alters intravascular fluid dynamics and contributes to the regulation of circulating volume.

Function as a Transport and Binding Protein

Albumin serves as a key non-specific carrier protein for various endogenous and exogenous substances. Zenalb 20% provides binding sites that facilitate the transport of molecules such as free fatty acids, bilirubin, thyroid hormones, and certain medicinal products and toxins. This binding capacity modulates the distribution, metabolism, and elimination kinetics of these circulating substances.

Official Administration Guidelines for Zenalb 20%

Zenalb 20% is a highly concentrated solution of Human Albumin (200 g/L or 20%) supplied in vials, and its administration is strictly governed by clinical protocols.

Feature	Official Instruction / Label Rule
Route of administration:	Intravenous administration only, delivered by infusion.
Preparation constraints:	The solution may be administered undiluted or mixed only with compatible isotonic solutions, such as 5% glucose or 0.9% sodium chloride. It must not be diluted with water for injections, as this may lead to red blood cell breakdown in the recipient.
Special handling:	The solution must be visually inspected for turbidity, deposits, or discoloration prior to use, and any cloudy solution must be discarded.
Administration setting:	Use is restricted to a hospital or clinical setting under medical supervision.

Official Dosing and Scheduling Principles

The dosage and rate of infusion for Zenalb 20% are not fixed and must be adjusted to the patient's individual requirements based on body weight, clinical status, and ongoing losses.

• Adult Dosing Examples: For the emergency management of hypovolemia, a common initial dose is 25 g. For the management of hypoalbuminemia, the typical adult range is often 50 g to 75 g.
• Frequency: Repeat dosing, such as a second 25 g dose for hypovolemia, may be given if an adequate circulatory response is not achieved within 15 to 30 minutes. For certain conditions like acute nephrosis, a dose of 25 g is administered once a day for 7 to 10 days.
• Pediatric Use: For hypovolemia in children under 13 years, the labeled dose range is 2.5 g to 12.5 g or 0.5 g to 1 g/kg of body weight.
• Maximum Dose: The total daily dose should not exceed 2 g of Albumin per kg of body weight.

Zenalb 20%: Overview of Studies

---

Research Focus on Intended Use

Research has investigated the substance for its intended use in managing conditions associated with low serum albumin, such as hypovolemia and hypoalbuminemia, through a number of clinical trials. The studies primarily investigated changes in measured parameters related to plasma volume expansion and albumin concentration over various timeframes.

• Initial Findings: Early-phase research examined whether participants receiving the substance demonstrated measured changes in key physiological indicators compared to control groups. The studies evaluated the substance when administered according to specific, standardized research protocols.
• Long-Term Exploration: Further research has examined long-term data collection points in specific populations with chronic conditions. These studies reviewed measured parameters over extended periods. Evidence remains limited regarding the long-term impact beyond two years of consistent use, with most studies focusing on acute and sub-acute conditions.

---

Adverse Event Reporting in Studies

Studies included a systematic collection of adverse event data through the collection of data from participants who received the substance doses used in the trials. The focus was on monitoring the frequency and type of events observed.

• Observed Adverse Events: Commonly observed adverse events included flushing, hives (urticaria), and fever. Researchers noted the frequency and duration of these events across the study population.
• Serious Adverse Events: Clinical trial reports detail the types and frequency of serious adverse events that occurred during the research period. These events were subject to continuous monitoring by the study teams, consistent with regulatory guidelines.

---

Research in Specific Populations

Studies were conducted to understand changes and adverse events observed in different groups of people based on age and pre-existing conditions.

• Kidney or Liver Impairment: Specific evaluations were conducted for participants with mild to severe kidney or liver impairment to explore measured changes in these groups and to examine data related to the substance's metabolism.

Common questions about Zenalb 20% (FAQ)

Q: How is Zenalb 20% different from a standard saline IV solution?

Zenalb 20% and standard saline (0.9% Sodium Chloride) function differently in the body. Standard saline is an isotonic solution, primarily replacing salt and water.

Zenalb 20%, as an albumin solution, is hyperoncotic, meaning its high protein concentration exerts Colloid Osmotic Pressure (COP). This COP actively draws fluid from body tissues into the bloodstream to stabilize circulation and fluid pressure, a function that saline does not perform.

Q: What is the difference between Zenalb 20% and a 5% albumin solution?

Zenalb 20% contains a protein concentration that is approximately four times higher than 4%-5% albumin solutions.

Zenalb 20% is classified as hyperoncotic, giving it a stronger fluid-drawing effect. This concentrated format is often used when fluid restriction is desired while achieving significant volume expansion.

Q: Does Zenalb 20% replace lost blood or is it only for fluid volume?

Zenalb 20% is classified as a plasma volume expander, and its primary function is to regulate and restore circulating fluid volume and fluid pressure.

Official administration documents confirm that it must not be mixed with whole blood or packed red blood cells in the infusion line, indicating it is not used as a replacement for blood or oxygen-carrying capacity.

Q: Does Zenalb 20% contain sodium or other electrolytes?

Yes, Zenalb 20% contains the electrolyte sodium in its specific formulation. Specific regulatory labels cite sodium levels generally between 50 to 140 mmol/L.

Due to this composition, the solution is officially described as a low electrolyte solution compared to some lower concentration albumin products.

Q: How quickly does Zenalb 20% start to work after the infusion begins?

The circulatory effects are generally rapid due to the function of albumin. Regulatory guidelines note that a circulatory response is typically assessed 15 to 30 minutes after administration, particularly when treating low blood volume.

The duration of the volume expansion effect may persist for many hours depending on the patient's individual fluid status.

Q: How long does the effect of Zenalb 20% on fluid balance typically last?

The albumin protein itself has a long biological half-life in the body, typically estimated to be about 18 to 36 days.

However, the immediate fluid-balancing and volume-expanding effects of the infusion are more acute and the duration can persist for many hours, depending on the patient's clinical needs.

Q: What are the specific signs that indicate the medicine is working correctly?

The expected response is monitored by regularly measuring haemodynamic performance, which indicates the adequacy of circulating volume.

Official guidance specifies that healthcare providers judge the response by monitoring arterial blood pressure, pulse rate, and central venous pressure.

Q: Why is blood pressure and heart rate monitored so closely during the infusion?

The intensive monitoring of hemodynamic performance (like blood pressure and pulse rate) is mandated by regulatory guidelines to guard against the risks of circulatory overload (hypervolaemia).

This continuous assessment helps to assess the overall response of the patient, which informs the healthcare team's decisions.

Q: Why might Zenalb 20% cause a fast heart rate (tachycardia)?

A fast heart rate (tachycardia) is listed as an uncommon side effect in the official safety profile.

According to warnings, this may be a symptom of circulatory overload (hypervolaemia), which is a serious risk factor that requires close monitoring and possible adjustment of the infusion rate.

Q: What are the signs of a serious or anaphylactic reaction to the infusion?

A severe allergic reaction (anaphylaxis) is a rare but serious adverse event that mandates immediate discontinuation of the infusion.

Signs of this type of reaction require prompt medical attention and may include skin rash or hives, severe dizziness, difficulty breathing, or swelling of the face, tongue, or throat.

Q: Is feeling dizzy a side effect that requires the infusion to be stopped?

Dizziness can be a symptom associated with the uncommon side effect of hypotension (low blood pressure), or it may be a sign of a more serious severe allergic reaction.

Official safety constraints indicate that if a severe reaction is suspected, the infusion should be stopped immediately by the qualified healthcare professional.

Q: Is it possible to have an allergic reaction to one of the non-albumin ingredients, like caprylate?

The medicine is contraindicated (must not be used) in patients with a known hypersensitivity to albumin preparations or any of the excipients (inactive ingredients) in the solution.

Excipients often include stabilizers such as sodium caprylate or sodium acetyltryptophanate, which may be the cause of hypersensitivity in certain individuals.

Q: What type of medical professionals are qualified to administer Zenalb 20%?

Zenalb 20% is a prescription-only medicine that must be administered by a qualified healthcare professional.

Official administration constraints state that its use is restricted to a clinical or hospital setting under medical supervision.

Q: Does Zenalb 20% need to be warmed up before it is infused?

The product will typically be allowed to reach room temperature before administration, especially if it has been stored in a refrigerator.

Furthermore, if large volumes of the solution are being administered to a patient, the product is often warmed to room or body temperature prior to use.

Q: How is the source plasma screened to ensure the safety of the product?

Regulatory information indicates that all units of human plasma used to manufacture Zenalb 20% are sourced from FDA-approved blood establishments only.

This plasma is subjected to specific testing protocols and the manufacturing process is designed to minimize potential risks, consistent with international standards for plasma-derived products.

Q: What is the process that ensures the removal of potential viruses from the solution?

The manufacturing process includes several mandated steps effective for viral reduction and removal to minimize risks associated with plasma-derived products.

These processes include Cohn cold-ethanol fractionation, ultra- and diafiltration, and a final container pasteurization procedure which involves heating the solution to 60 C for 10-11 hours.

Q: Can Zenalb 20% be safely used in patients who have kidney problems?

Official warnings state that Zenalb 20% should be used with special caution in conditions involving renal impairment or renal anuria.

This is due to the volume-expanding effects of the drug, which require patients to be carefully monitored for signs of fluid overload or hyperhydration.

Q: Is Zenalb 20% appropriate for patients with existing liver disease or cirrhosis?

While not explicitly listed as a blanket contraindication, albumin is often used in the treatment of specific complications of cirrhosis, such as Hepatorenal Syndrome.

Official research reports note that specific evaluations were conducted for participants with severe liver impairment to explore the effects of the substance in this group.

Q: Is Zenalb 20% considered safe to use for long-term treatment of low albumin?

The albumin protein does have a long half-life in the body, typically estimated to be 18 to 36 days.

However, official regulatory documents indicate that the evidence remains limited regarding the long-term impact of consistent use for periods extending beyond acute and sub-acute conditions.

Q: Can Zenalb 20% affect the results of routine blood tests done after the infusion?

Albumin acts as a key carrier protein that naturally binds and transports various molecules, including hormones and certain medicinal products, throughout the circulation.

Because of this transport function, the presence of infused albumin may be relevant to the clinical interpretation of subsequent laboratory tests.

How to Store and Dispose of Zenalb 20%

Zenalb 20% must be stored within a specific temperature range and protected from light and freezing to maintain its integrity, as required by official labeling.

Storage Conditions

Zenalb 20% must be stored at a temperature between 2 C and 25 C and it is strictly required not to freeze the product. The solution must be kept in its original container and in the outer carton to ensure it is protected from light.

Stability and Handling

The medicine must be stored out of the sight and reach of children. The solution should not be used if it appears cloudy or has deposits. Once the container has been opened, the contents must be used within 3 hours.

Disposal Instructions

Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. The medicine should not be disposed of via wastewater or household waste.